1: Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL; ANDROMEDA Trial Investigators. Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis. N Engl J Med. 2021 Jul 1;385(1):46-58. doi: 10.1056/NEJMoa2028631. PMID: 34192431.
2: Palladini G, Kastritis E, Maurer MS, Zonder J, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Bumma N, Kaufman JL, Medvedova E, Kovacsovics T, Rosenzweig M, Sanchorawala V, Qin X, Vasey SY, Weiss BM, Vermeulen J, Merlini G, Comenzo RL. Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA. Blood. 2020 Jul 2;136(1):71-80. doi: 10.1182/blood.2019004460. PMID: 32244252; PMCID: PMC7332897.
3: Bhatt P, Kloock C, Comenzo R. Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse. Curr Oncol. 2023 Feb 15;30(2):2322-2347. doi: 10.3390/curroncol30020179. PMID: 36826140; PMCID: PMC9954856.
4: Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac Amyloidosis. Circulation. 2017 Apr 4;135(14):1357-1377. doi: 10.1161/CIRCULATIONAHA.116.024438. PMID: 28373528; PMCID: PMC5392416.
5: Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M; International Myeloma Working Group. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010 Jun;24(6):1121-7. doi: 10.1038/leu.2010.60. Epub 2010 Apr 22. PMID: 20410922; PMCID: PMC7020664.
6: Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H; International Myeloma Working Group. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014 Feb;28(2):269-77. doi: 10.1038/leu.2013.247. Epub 2013 Aug 26. PMID: 23974982.
7: Comenzo RL. Shedding Tears to Clear the Way. Hematol Oncol Clin North Am. 2020 Dec;34(6):xiii-xiv. doi: 10.1016/j.hoc.2020.09.002. Epub 2020 Sep 30. PMID: 33099436.
8: Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG; International Myeloma Working Group. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009 Feb;23(2):215-24. doi: 10.1038/leu.2008.307. Epub 2008 Nov 20. PMID: 19020545.
9: Ballesteros-Pomar M, Villar-Taibo R, Calleja-Fernández A, Pintor-de-la-Maza B, Álvarez-Del-Campo C, Vidal-Casariego A, Cano-Rodríguez I. Abordaje nutricional del enfermo oncohematológico. Best-practice en España. Nutr Hosp. 2016 Jun 3;33(Suppl 1):180. Spanish. doi: 10.20960/nh.180. PMID: 27269220.
10: Chari A, Vogl DT, Gavriatopoulou M, Nooka AK, Yee AJ, Huff CA, Moreau P, Dingli D, Cole C, Lonial S, Dimopoulos M, Stewart AK, Richter J, Vij R, Tuchman S, Raab MS, Weisel KC, Delforge M, Cornell RF, Kaminetzky D, Hoffman JE, Costa LJ, Parker TL, Levy M, Schreder M, Meuleman N, Frenzel L, Mohty M, Choquet S, Schiller G, Comenzo RL, Engelhardt M, Illmer T, Vlummens P, Doyen C, Facon T, Karlin L, Perrot A, Podar K, Kauffman MG, Shacham S, Li L, Tang S, Picklesimer C, Saint-Martin JR, Crochiere M, Chang H, Parekh S, Landesman Y, Shah J, Richardson PG, Jagannath S. Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. N Engl J Med. 2019 Aug 22;381(8):727-738. doi: 10.1056/NEJMoa1903455. PMID: 31433920.
11: Zhang Y, Comenzo RL. Immunotherapy in AL Amyloidosis. Curr Treat Options Oncol. 2022 Jul;23(7):1059-1071. doi: 10.1007/s11864-021-00922-4. Epub 2022 May 30. PMID: 35635625.
12: Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, Weiss BM, Krishnan A, Lentzsch S, Comenzo R, Wang J, Nottage K, Chiu C, Khokhar NZ, Ahmadi T, Lonial S. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017 Aug 24;130(8):974-981. doi: 10.1182/blood-2017-05-785246. Epub 2017 Jun 21. PMID: 28637662; PMCID: PMC5570682.
13: Comenzo RL. Amyloidosis. Curr Treat Options Oncol. 2006 May;7(3):225-36. doi: 10.1007/s11864-006-0015-8. PMID: 16615878.
14: Rosenzweig M, Comenzo RL. Liver and Gastrointestinal Involvement. Hematol Oncol Clin North Am. 2020 Dec;34(6):1081-1090. doi: 10.1016/j.hoc.2020.09.001. Epub 2020 Oct 1. PMID: 33099425.
15: Gertz MA, Cohen AD, Comenzo RL, Kastritis E, Landau HJ, Libby EN, Liedtke M, Sanchorawala V, Schönland S, Wechalekar A, Zonder JA, Palladini G, Walling J, Guthrie S, Nie C, Karp C, Jin Y, Kinney GG, Merlini G. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial. Blood. 2023 Oct 5;142(14):1208-1218. doi: 10.1182/blood.2022019406. PMID: 37366170; PMCID: PMC10644097.
16: Merlini G, Comenzo RL, Seldin DC, Wechalekar A, Gertz MA. Immunoglobulin light chain amyloidosis. Expert Rev Hematol. 2014 Feb;7(1):143-56. doi: 10.1586/17474086.2014.858594. Epub 2013 Dec 18. PMID: 24350907.
17: Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med. 1997 Sep 25;337(13):898-909. doi: 10.1056/NEJM199709253371306. PMID: 9302305.
18: Suzuki K, Wechalekar AD, Kim K, Shimazaki C, Kim JS, Ikezoe T, Min CK, Zhou F, Cai Z, Chen X, Iida S, Katoh N, Fujisaki T, Shin HJ, Tran N, Qin X, Vasey SY, Tromp B, Weiss BM, Comenzo RL, Kastritis E, Lu J. Daratumumab plus bortezomib, cyclophosphamide, and dexamethasone in Asian patients with newly diagnosed AL amyloidosis: subgroup analysis of ANDROMEDA. Ann Hematol. 2023 Apr;102(4):863-876. doi: 10.1007/s00277-023-05090-z. Epub 2023 Mar 2. PMID: 36862168; PMCID: PMC9998577.
19: Mann H, Katiyar V, Varga C, Comenzo RL. Smoldering multiple myeloma - Past, present, and future. Blood Rev. 2022 Mar;52:100869. doi: 10.1016/j.blre.2021.100869. Epub 2021 Jul 22. PMID: 34312016.
20: Wong SW, Comenzo RL. CD38 Monoclonal Antibody Therapies for Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):635-45. doi: 10.1016/j.clml.2015.07.642. Epub 2015 Aug 5. PMID: 26443328.
21: Comenzo RL. Out, Out--Making Amyloid's Candle Briefer. N Engl J Med. 2015 Sep 17;373(12):1167-9. doi: 10.1056/NEJMe1508746. PMID: 26376140.
22: Comenzo RL. Primary systemic amyloidosis. Curr Treat Options Oncol. 2000 Apr;1(1):83-9. doi: 10.1007/s11864-000-0018-9. PMID: 12057064.
23: Comenzo RL. Systemic immunoglobulin light-chain amyloidosis. Clin Lymphoma Myeloma. 2006 Nov;7(3):182-5. doi: 10.3816/CLM.2006.n.056. PMID: 17229332.
24: Minnema MC, Dispenzieri A, Merlini G, Comenzo RL, Kastritis E, Wechalekar AD, Grogan M, Witteles R, Ruberg FL, Maurer MS, Tran N, Qin X, Vasey SY, Weiss BM, Vermeulen J, Jaccard A. Outcomes by Cardiac Stage in Patients With Newly Diagnosed AL Amyloidosis: Phase 3 ANDROMEDA Trial. JACC CardioOncol. 2022 Nov 15;4(4):474-487. doi: 10.1016/j.jaccao.2022.08.011. PMID: 36444227; PMCID:
PMC9700253.
25: Weiss BM, Wong SW, Comenzo RL. Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis. Blood. 2016 May 12;127(19):2275-80. doi: 10.1182/blood-2015-11-681650. Epub 2016 Feb 23. PMID: 26907632.
26: Bianchi G, Zhang Y, Comenzo RL. AL Amyloidosis: Current Chemotherapy and Immune Therapy Treatment Strategies: <i>JACC: CardioOncology</i> State-of-the-Art Review. JACC CardioOncol. 2021 Oct 19;3(4):467-487. doi: 10.1016/j.jaccao.2021.09.003. PMID: 34729520; PMCID: PMC8543128.
27: Varga C, Lentzsch S, Comenzo RL. Beyond NEOD001 for systemic light-chain amyloidosis. Blood. 2018 Nov 1;132(18):1992-1993. doi: 10.1182/blood-2018-07-865857. Epub 2018 Sep 21. PMID: 30242086.
28: Comenzo RL. Plasma cell neoplasms, their precursor States, and their prediction of organ damage. J Clin Oncol. 2014 Sep 1;32(25):2679-82. doi: 10.1200/JCO.2014.56.2892. Epub 2014 Jul 14. PMID: 25024079.
29: Mann H, Comenzo RL. Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date. Onco Targets Ther. 2022 Jul 22;15:799-813. doi: 10.2147/OTT.S305429. PMID: 35912273; PMCID: PMC9327779.
30: Comenzo RL. How I treat amyloidosis. Blood. 2009 Oct 8;114(15):3147-57. doi: 10.1182/blood-2009-04-202879. Epub 2009 Jul 17. PMID: 19617578.
31: Varga C, Titus SE, Toskic D, Comenzo RL. Use of novel therapies in the treatment of light chain amyloidosis. Blood Rev. 2019 Sep;37:100581. doi: 10.1016/j.blre.2019.05.005. Epub 2019 May 22. PMID: 31167719.
32: Varga C, Dorbala S, Lousada I, Polydefkis MJ, Wechalekar A, Maurer MS, Comenzo RL. The diagnostic challenges of cardiac amyloidosis: A practical approach to the two main types. Blood Rev. 2021 Jan;45:100720. doi: 10.1016/j.blre.2020.100720. Epub 2020 Jun 23. PMID: 32616304.
33: Dima D, Dower J, Comenzo RL, Varga C. Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy. Cancer Manag Res. 2020 Aug 26;12:7891-7903. doi: 10.2147/CMAR.S212526. PMID: 32904669; PMCID: PMC7457558.
34: Chaulagain CP, Comenzo RL. How we treat systemic light-chain amyloidosis. Clin Adv Hematol Oncol. 2015 May;13(5):315-24. PMID: 26352777.
35: Comenzo RL. Managing systemic light-chain amyloidosis. J Natl Compr Canc Netw. 2007 Feb;5(2):179-87. doi: 10.6004/jnccn.2007.0018. PMID: 17335687.
36: Dubrey SW, Comenzo RL. Amyloid diseases of the heart: current and future therapies. QJM. 2012 Jul;105(7):617-31. doi: 10.1093/qjmed/hcr259. Epub 2012 Jan 5. PMID: 22223674.
37: Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala V, Landau H, Falk R, Wells K, Solomon A, Wechalekar A, Zonder J, Dispenzieri A, Gertz M, Streicher H, Skinner M, Kyle RA, Merlini G. Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia. 2012 Nov;26(11):2317-25. doi: 10.1038/leu.2012.100. Epub 2012 Apr 5. PMID: 22475872.
38: Zhang Y, Godara A, Pan S, Toskic D, Mann H, Sborov D, Comenzo R, Kansagra A. Belantamab mafodotin in patients with relapsed/refractory AL amyloidosis with myeloma. Ann Hematol. 2022 Sep;101(9):2119-2121. doi: 10.1007/s00277-022-04890-z. Epub 2022 Jul 12. PMID: 35821344.
39: Richardson PG, Delforge M, Beksac M, Wen P, Jongen JL, Sezer O, Terpos E, Munshi N, Palumbo A, Rajkumar SV, Harousseau JL, Moreau P, Avet-Loiseau H, Lee JH, Cavo M, Merlini G, Voorhees P, Chng WJ, Mazumder A, Usmani S, Einsele H, Comenzo R, Orlowski R, Vesole D, Lahuerta JJ, Niesvizky R, Siegel D, Mateos MV, Dimopoulos M, Lonial S, Jagannath S, Bladé J, Miguel JS, Morgan G, Anderson KC, Durie BG, Sonneveld P. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2012 Apr;26(4):595-608. doi: 10.1038/leu.2011.346. Epub 2011 Dec 23. PMID: 22193964.
40: Sanchorawala V, Palladini G, Minnema MC, Jaccard A, Lee HC, Gibbs S, Mollee P, Venner C, Lu J, Schönland S, Gatt M, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Chauveau D, Gries KS, Fastenau J, Tran NP, Qin X, Vasey SY, Weiss BM, Vermeulen J, Ho KF, Merlini G, Comenzo RL, Kastritis E, Wechalekar AD. Health-related quality of life in
patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study. Am J Hematol. 2022 Jun 1;97(6):719-730. doi: 10.1002/ajh.26536. Epub 2022 Mar 30. PMID: 35293006.
41: Varga C, Comenzo RL. High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel anti-plasma cell therapy: a comprehensive review. Bone Marrow Transplant. 2019 Apr;54(4):508-518. doi: 10.1038/s41409-018-0284-4. Epub 2018 Aug 8. PMID: 30089901.
42: Cohen AD, Comenzo RL. Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy. Hematology Am Soc Hematol Educ Program. 2010;2010:287-94. doi: 10.1182/asheducation-2010.1.287. PMID: 21239808.
43: Comenzo RL. LECT2 makes the amyloid list. Blood. 2014 Mar 6;123(10):1436-7. doi: 10.1182/blood-2014-01-549758. PMID: 24627547.
44: Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002 Jun 15;99(12):4276-82. doi: 10.1182/blood.v99.12.4276. PMID: 12036853.
45: Godara A, Riesenburger RI, Zhang DX, Varga C, Fogaren T, Siddiqui NS, Yu A, Wang A, Mastroianni M, Dowd R, Nail TJ, McPhail ED, Kurtin PJ, Theis JD, Toskic D, Arkun K, Pilichowska M, Kryzanski J, Patel AR, Comenzo R. Association between spinal stenosis and wild-type ATTR amyloidosis. Amyloid. 2021 Dec;28(4):226-233. doi: 10.1080/13506129.2021.1950681. Epub 2021 Jul 15. PMID: 34263670.
46: Palladini G, Comenzo RL. The challenge of systemic immunoglobulin light-chain amyloidosis (Al). Subcell Biochem. 2012;65:609-42. doi: 10.1007/978-94-007-5416-4_22. PMID: 23225018.
47: Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, Comenzo R, Du J, Durie BGM, San Miguel J, Einsele H, Chen WM, Garderet L, Pietrantuono G, Hillengass J, Kyle RA, Moreau P, Lahuerta JJ, Landgren O, Ludwig H, Larocca A, Mahindra A, Cavo M, Mazumder A, McCarthy PL, Nouel A, Rajkumar SV, Reiman A, Riva E, Sezer O, Terpos E, Turesson I, Usmani S, Weiss BM, Palumbo A; International Myeloma Working Group. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol. 2017 Feb 1;28(2):228-245. doi: 10.1093/annonc/mdw606. Erratum in: Ann Oncol. 2017 May 24;: PMID: 27864218.
48: Fernández de Larrea C, Kyle RA, Durie BG, Ludwig H, Usmani S, Vesole DH, Hajek R, San Miguel JF, Sezer O, Sonneveld P, Kumar SK, Mahindra A, Comenzo R, Palumbo A, Mazumber A, Anderson KC, Richardson PG, Badros AZ, Caers J, Cavo M, LeLeu X, Dimopoulos MA, Chim CS, Schots R, Noeul A, Fantl D, Mellqvist UH, Landgren O, Chanan-Khan A, Moreau P, Fonseca R, Merlini G, Lahuerta JJ, Bladé J,
Orlowski RZ, Shah JJ; International Myeloma Working Group. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013 Apr;27(4):780-91. doi: 10.1038/leu.2012.336. Epub 2012 Nov 21. PMID: 23288300; PMCID: PMC4112539.
49: Chaulagain CP, Comenzo RL. New insights and modern treatment of AL amyloidosis. Curr Hematol Malig Rep. 2013 Dec;8(4):291-8. doi: 10.1007/s11899-013-0175-0. PMID: 24026941.
50: Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksaç M, Anderson KC, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, Kumar S, Giralt S, Munshi NC, Jagannath S; International Myeloma Workshop Consensus Panel 3. Consensus recommendations for standard investigative workup: report of the International
Myeloma Workshop Consensus Panel 3. Blood. 2011 May 5;117(18):4701-5. doi: 10.1182/blood-2010-10-299529. Epub 2011 Feb 3. PMID: 21292778.
51: Villegas JD, Zapata MC, Jaramillo MC, Orozco E, Suárez JC. A case report of fat embolism syndrome: Treatment and neurological and cognitive rehabilitation. Biomedica. 2019 Mar 31;39(1):22-32. English, Spanish. doi: 10.7705/biomedica.v39i1.4438. PMID: 31021544.
52: Comenzo RL. Commentary on No Monoclonal Protein in a Patient with CRAB Features. Clin Chem. 2021 Nov 26;67(12):1588-1589. doi: 10.1093/clinchem/hvab212. PMID: 34850844.
53: Sullivan JC, Comenzo R. Peripheral agglutination and hemolytic anemia following minor ABO-mismatch hematopoietic progenitor cell transplantation. Blood. 2022 Dec 1;140(22):2412. doi: 10.1182/blood.2022018097. PMID: 36454591.
54: Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo R, Sonneveld P, Kumar S, Hajek R, Giralt S, Bringhen S, Anderson KC, Richardson PG, Cavo M, Davies F, Bladé J, Einsele H, Dimopoulos MA, Spencer A, Dispenzieri A, Reiman T, Shimizu K, Lee JH, Attal M, Boccadoro M, Mateos M, Chen W, Ludwig H, Joshua D, Chim J, Hungria V, Turesson I, Durie BG, Lonial S; IMWG. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia. 2009 Oct;23(10):1716-30. doi: 10.1038/leu.2009.122. Epub 2009 Jun 4. PMID: 19494840.
55: Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, Merlini G, Moreau P, Ronco P, Sanchorawala V, Sezer O, Solomon A, Grateau G. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am J Hematol. 2005 Aug;79(4):319-28. doi: 10.1002/ajh.20381. PMID: 16044444.
56: Palladini G, Dispenzieri A, Gertz M, Kumar S, Wechalekar A, Hawkins PN, Schönland S, Hegenbart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G. Reply to S. Girnius et al. J Clin Oncol. 2013 Jul 20;31(21):2750-1. doi: 10.1200/JCO.2013.49.2512. PMID: 24040662.
57: Inaugural Amyloidosis Forum Panelists; Lousada I. The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis. Orphanet J Rare Dis. 2020 Sep 29;15(1):268. doi: 10.1186/s13023-020-01525-2. PMID: 32993758; PMCID: PMC7523334.
58: Luján-Martínez D, Ruiz-Marín M, Peña-Ros E, Albarracín-Marín-Blázquez A, Candel-Arenas M. Frontal lobe metastases as the initial presentation of follicular thyroid carcinoma [Metástasis en el lóbulo frontal como primera manifestación clínica de un carcinoma folicular de tiroides]. Cir Cir. 2018;86(6):562-565. Spanish. doi: 10.24875/CIRU.18000207. PMID: 30361707.
59: Merlini G, Lousada I, Ando Y, Dispenzieri A, Gertz MA, Grogan M, Maurer MS, Sanchorawala V, Wechalekar A, Palladini G, Comenzo RL. Rationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosis. Leukemia. 2016 Oct;30(10):1979-1986. doi: 10.1038/leu.2016.191. Epub 2016 Jul 15. PMID: 27416985; PMCID: PMC5056962.
60: Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Kumar S, Munshi NC, Dispenzieri A, Kyle R, Merlini G, San Miguel J, Ludwig H, Hajek R, Jagannath S, Blade J, Lonial S, Dimopoulos MA, Einsele H, Barlogie B, Anderson KC, Gertz M, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Richardson PG, Niesvizky R, Rajkumar SV, Durie BG; IMWG. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009 Oct;23(10):1904-12. doi: 10.1038/leu.2009.127. Epub 2009 Jun 25. PMID: 19554029.
61: Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Hungria V, Joshua D, Ludwig H, Mehta J, Morales AR, Morgan G, Nouel A, Oken M, Powles R, Roodman D, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van Ness B; Scientific Advisors of the International Myeloma Foundation. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J. 2003;4(6):379-98. Erratum in: Hematol J. 2004;5(3):285. PMID: 14671610.
62: Comenzo RL. Who knows how to treat systemic light chain amyloidosis? Oncology (Williston Park). 2011 Jun;25(7):626, 628-9, 632-3. PMID: 21888262.
63: Dispenzieri A, Merlini G, Comenzo RL. Amyloidosis: 2008 BMT Tandem Meetings (February 13-17, San Diego). Biol Blood Marrow Transplant. 2008 Jan;14(1 Suppl 1):6-11. doi: 10.1016/j.bbmt.2007.10.026. Erratum in: Biol Blood Marrow Transplant. 2008 Nov;14(11):1317-8. PMID: 18162215.
64: Godara A, Toskic D, Albanese J, Rosenthal B, Siddiqui NS, Kugelmass A, Zhou P, Fogaren T, Varga C, Landau HJ, Comenzo RL. Involved free light chains <10 mg/L with treatment predict better outcomes in systemic light-chain amyloidosis. Am J Hematol. 2021 Jan;96(1):E20-E23. doi: 10.1002/ajh.26025. Epub 2020 Nov 5. PMID: 33068021; PMCID: PMC8436337.
65: Dimopoulos M, Terpos E, Comenzo RL, Tosi P, Beksac M, Sezer O, Siegel D, Lokhorst H, Kumar S, Rajkumar SV, Niesvizky R, Moulopoulos LA, Durie BG; IMWG. International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma. Leukemia. 2009 Sep;23(9):1545-56. doi: 10.1038/leu.2009.89.
Epub 2009 May 7. PMID: 19421229.
66: Kumar S, Dispenzieri A, Bhutani D, Gertz M, Wechalekar A, Palladini G, Comenzo R, Fonseca R, Jaccard A, Kastritis E, Schönland S, la Porte C, Pei H, Tran N, Merlini G. Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study. Amyloid. 2023 Sep;30(3):268-278. doi: 10.1080/13506129.2022.2164488. Epub 2023 Feb 13. PMID: 36779691.
67: Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Bladé J, Comenzo RL, Sezer O, Palumbo A, Harousseau JL, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Cavo M, Rajkumar SV, Durie BG, San Miguel J. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010 Nov 20;28(33):4976-84. doi: 10.1200/JCO.2010.30.8791. Epub 2010 Oct 18. PMID: 20956629.
68: Luo MM, Zhu PP, Nnane I, Xiong Y, Merlini G, Comenzo RL, Kastritis E, Wechalekar AD, Weiss BM, Tran N, Qin X, Vermeulen J, Sharma A, Sun YN, Zhou H. Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis. J Clin Pharmacol. 2022 May;62(5):656-669. doi: 10.1002/jcph.1994. Epub 2021 Nov 28. PMID: 34708423.
69: Comenzo RL. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis. Contrib Nephrol. 2007;153:195-210. doi: 10.1159/000096768. PMID: 17075231.
70: Comenzo RL. Hematopoietic cell transplantation for primary systemic amyloidosis: what have we learned. Leuk Lymphoma. 2000 Apr;37(3-4):245-58. doi: 10.3109/10428190009089426. PMID: 10752977.
71: Carballo-Diéguez A, Avila MM, Balán IC, Marone R, Pando MA, Barreda V. Presentación del estudio "Links" de hombres que tienes sexo con hombres en Buenos Aires, Argentina. Actual SIDA. 2011 Mar;19(71):21-25. PMID: 25264397; PMCID: PMC4175515.
72: Terpos E, Dimopoulos MA, Sezer O, Roodman D, Abildgaard N, Vescio R, Tosi P, Garcia-Sanz R, Davies F, Chanan-Khan A, Palumbo A, Sonneveld P, Drake MT, Harousseau JL, Anderson KC, Durie BG; International Myeloma Working Group. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia. 2010 Oct;24(10):1700-12. doi: 10.1038/leu.2010.173. Epub 2010 Sep 2. PMID: 20811404.
73: Godara A, Wang AY, Arkun K, Fogaren T, Qamar AS, McPhail ED, Kryzanski J, Riesenburger R, Comenzo R. Unraveling a rare cause of spinal stenosis: Coexistent AL and ATTR amyloidosis involving the ligamentum flavum. Surg Neurol Int. 2022 Jan 12;13:12. doi: 10.25259/SNI_1235_2021. PMID: 35127212; PMCID: PMC8813631.
74: Dima D, Hu X, Dower J, Zhang D, Comenzo R, Varga C. Pattern of use and efficacy of daratumumab-based therapy in patients with relapsed/refractory light chain amyloidosis in a real-world setting: a single institution experience. Leuk Lymphoma. 2022 May;63(5):1246-1250. doi: 10.1080/10428194.2021.2018585. Epub 2022 Jan 2. PMID: 34978254.
75: Chaulagain CP, Comenzo RL. Stigmata of amyloidosis; external manifestations of internal disease. Br J Haematol. 2019 Jul;186(1):10. doi: 10.1111/bjh.15885. Epub 2019 Mar 27. PMID: 30916377.
76: Rao M, Lamont JL, Chan J, Concannon TW, Comenzo R, Ratichek SJ, Avendano EE. Serum Free Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias: Future Research Needs: Identification of Future Research Needs From Comparative Effectiveness Review No. 73 [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Sep. Report No.: 12-EHC135-EF. PMID: 23678513.
77: Stadtmauer EA, Lonial S, Vesole DH, Abonour R, Alsina M, Badros A, Comenzo R, Durie B, Giralt S, Hussein M, Jakubowiak A, Mehta J, Niesvizky R, Orlowski R, Siegel D, Singhal S, Vescio R, Wang M, Zangari M, Munshi NC. A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings. Clin Adv Hematol Oncol. 2007 Oct;5(10 Suppl 15):7-19, quiz 21-2. PMID: 18000495.
78: Hu X, Wu CH, Cowan JM, Comenzo RL, Varga C. Outcomes of patients with multiple myeloma harboring chromosome 1q gain/amplification in the era of modern therapy. Ann Hematol. 2022 Feb;101(2):369-378. doi: 10.1007/s00277-021-04704-8. Epub 2021 Nov 8. PMID: 34748077.
79: Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski R, Kumar S, Usmani S, Roodman D, Niesvizky R, Einsele H, Anderson KC, Dimopoulos MA, Avet-Loiseau H, Mellqvist UH, Turesson I, Merlini G, Schots R, McCarthy P, Bergsagel L, Chim CS, Lahuerta JJ, Shah J, Reiman A, Mikhael J, Zweegman S, Lonial S, Comenzo R, Chng WJ, Moreau P, Sonneveld P, Ludwig H, Durie BG, Miguel JF. New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia. 2014 Mar;28(3):525-42. doi: 10.1038/leu.2013.350. Epub 2013 Nov 20. PMID: 24253022; PMCID: PMC4143389.
80: Premkumar VJ, Lentzsch S, Pan S, Bhutani D, Richter J, Jagannath S, Liedtke M, Jaccard A, Wechalekar AD, Comenzo R, Sanchorawala V, Royer B, Rosenzweig M, Valent J, Schönland S, Fonseca R, Wong S, Kapoor P. Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis. Blood Cancer J. 2021 Jan 11;11(1):10. doi: 10.1038/s41408-020-00397-w. PMID: 33431806; PMCID: PMC7801694.
81: Ma X, Zhou P, Kugelmass A, Toskic D, Warner M, Lee L, Fogaren T, Godara A, Wang M, Li Y, Yang L, Xu Q, Comenzo RL. A novel xenograft mouse model for testing approaches targeting human kappa light-chain diseases. Gene Ther. 2019 May;26(5):187-197. doi: 10.1038/s41434-019-0070-y. Epub 2019 Mar 29. PMID: 30926963.
82: Stott D, Papastefanou I, Paraschiv D, Clark K, Kametas NA. Serial hemodynamic monitoring to guide treatment of maternal hypertension leads to reduction in severe hypertension. Ultrasound Obstet Gynecol. 2017 Jan;49(1):95-103. doi: 10.1002/uog.17341. PMID: 27800645.
83: Godara A, Siddiqui NS, Lee LX, Toskic D, Fogaren T, Varga C, Comenzo RL. Dual Monoclonal Antibody Therapy in Patients With Systemic AL Amyloidosis and Cardiac Involvement. Clin Lymphoma Myeloma Leuk. 2020 Mar;20(3):184-189. doi: 10.1016/j.clml.2019.10.019. Epub 2020 Jan 2. PMID: 31983636.
84: Dower J, Dima D, Lalla M, Patel AR, Comenzo RL, Varga C. The use of PYP scan for evaluation of ATTR cardiac amyloidosis at a tertiary medical centre. Br J Cardiol. 2022 May 31;29(2):19. doi: 10.5837/bjc.2022.019. PMID: 36212788; PMCID: PMC9534106.
85: Pericot-Nierga I, Turbau-Recio J, Bragado I, Hernández M. Paciente con enfermedad de Creutzfeldt-Jakob que comenzó con una enfermedad de motoneurona [A patient with Creutzfeldt-Jakob disease presenting with a motoneurone disease]. Rev Neurol. 2020 Feb 1;70(3):118. Spanish. doi: 10.33588/rn.7003.2019438. PMID: 31994168.
86: Godara A, Zhou P, Kugelmass A, Ma X, Rosenthal B, Toskic D, Fogaren T, Varga C, Comenzo RL. Presence of soluble and cell-surface B-cell maturation antigen in systemic light-chain amyloidosis and its modulation by gamma-secretase inhibition. Am J Hematol. 2020 May;95(5):E110-E113. doi: 10.1002/ajh.25734. Epub 2020 Jan 29. PMID: 31951032.
87: George KM, Hernandez NS, Breton J, Cooper B, Dowd RS, Nail J, Yu A, Mastroianni M, Wang A, Godara A, Zhang D, Arkun K, Patel AR, Varga C, Soto O, Kryzanski J, Comenzo R, Riesenburger R. Increased thickness of lumbar spine ligamentum flavum in wild-type transthyretin amyloidosis. J Clin Neurosci. 2021 Feb;84:33-37. doi: 10.1016/j.jocn.2020.11.029. Epub 2020 Dec 31. PMID: 33485595.
88: Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Comenzo RL, De Castro CM, Djulbegovic B, Farag S, Huff CA, Meredith R, Schriber J, Shrieve D, Singhal S, Smith MR, Stockerl-Goldstein K, Vose JM, Weber D, Yahalom J, Yunus F; National Comprehensive Cancer Network (NCCN). Multiple myeloma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007 Feb;5(2):118-47. doi: 10.6004/jnccn.2007.0014. PMID: 17335683.
89: Waheed A, Fongemie J, Gopal S, Esham KS, Richardson-Weber L, Zhang L, Van Doren L, Buchsbaum RJ, Comenzo RL. Implementation and impact of a multidisciplinary coagulation factor stewardship program at an academic medical center. J Thromb Thrombolysis. 2020 Oct;50(3):715-717. doi: 10.1007/s11239-020-02071-1. PMID: 32107696.
90: Chaulagain CP, Diacovo JM, Elson L, Comenzo RL, Samaras C, Anwer F, Khouri J, Landau H, Valent J. Daratumumab-based Regimen in Treating Clonal Plasma Cell Neoplasms in Solid Organ Transplant Recipients. Clin Lymphoma Myeloma Leuk. 2020 Mar;20(3):e137-e143. doi: 10.1016/j.clml.2019.12.022. Epub 2020 Jan 8. PMID: 32029395; PMCID: PMC8183688.
91: Rosenzweig MA, Landau H, Seldin D, O'Hara C, Girnius S, Hanson N, Frosina D, Sedrak C, Arcila M, Comenzo RL, Giralt S, Gnjatic S, Jungbluth AA, Koehne G. Cancer-testis antigen expression and immunogenicity in AL amyloidosis. Blood Cancer J. 2012 Sep 14;2(9):e90. doi: 10.1038/bcj.2012.32. PMID: 22983433; PMCID: PMC3461704.
92: Cone Sullivan J, Conklin SE, Conrad S, Horowitz C, Diethelm M, Comenzo R. Therapeutic plasma exchange decreases plasma anti-SARS-CoV-2 spike IgG without increasing the proximate incidence of COVID-19. J Clin Apher. 2023 Dec;38(6):721-726. doi: 10.1002/jca.22087. Epub 2023 Sep 14. PMID: 37706521.
93: Dispenzieri A, Kastritis E, Wechalekar AD, Schönland SO, Kim K, Sanchorawala V, Landau HJ, Kwok F, Suzuki K, Comenzo RL, Berg D, Liu G, Kumar A, Faller DV, Merlini G. A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis. Leukemia. 2022 Jan;36(1):225-235. doi: 10.1038/s41375-021-01317-y. Epub 2021 Jun 24. PMID: 34168284; PMCID: PMC8727292.
94: Lahoud OB, Landau H, Nguyen J, Devlin S, Lendvai N, Weltz J, Ayorinde T, Chung DJ, Lesokhin AM, Kewalramani T, Korde N, Mailankody S, Landgren O, Giralt S, Comenzo RL, Hassoun H. Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach. Leuk Lymphoma. 2022 Sep;63(9):2126-2135. doi: 10.1080/10428194.2022.2062347. Epub 2022 Jun 1. PMID: 35648041; PMCID: PMC9703606.
95: Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E. American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant. 2015 Dec;21(12):2039-2051. doi: 10.1016/j.bbmt.2015.09.016. Epub 2015 Sep 30. PMID: 26428082; PMCID: PMC4757494.
96: Jakubowiak A, Usmani SZ, Krishnan A, Lonial S, Comenzo RL, Wang J, de Boer C, Deraedt W, Weiss BM, Schecter JM, Chari A. Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2021 Oct;21(10):701-710. doi: 10.1016/j.clml.2021.05.017. Epub 2021 Jun 9. PMID: 34274290.
97: Wong SW, Hegenbart U, Palladini G, Shah GL, Landau HJ, Warner M, Toskic D, Jaccard A, Hansen T, Bladé J, Cibeira MT, Kastritis E, Dispenzieri A, Wechalekar A, Varga C, Schönland SO, Comenzo RL. Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p. Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):e493-e499. doi: 10.1016/j.clml.2018.07.292. Epub 2018 Jul 25. PMID: 30104177; PMCID: PMC7441584.
98: Rao M, Yu WW, Chan J, Patel K, Comenzo R, Lamont JL, Ip S, Lau J. Serum Free. Light Chain Analysis for the Diagnosis, Management, and Prognosis of Plasma Cell Dyscrasias [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Aug. Report No.: 12-EHC102-EF. PMID: 23016162.
99: Premkumar V, Comenzo R, Lentzsch S. Venetoclax in Immunoglobulin Light Chain Amyloidosis: Is This the Beginning or the End? Clin Lymphoma Myeloma Leuk. 2019 Oct;19(10):686-688. doi: 10.1016/j.clml.2019.07.003. Epub 2019 Jul 15. PMID: 31399374; PMCID: PMC6954683.
100: Wong SW, Toskic D, Warner M, Varga C, Moreno-Koehler A, Fein D, Fogaren T, Lee L, Oliver CM, Guthrie SD, Comenzo RL. Primary Amyloidosis With Renal Involvement: Outcomes in 77 Consecutive Patients at a Single Center. Clin Lymphoma Myeloma Leuk. 2017 Nov;17(11):759-766. doi: 10.1016/j.clml.2017.06.004. Epub 2017 Jun 17. PMID: 28689003.
101: Cohan JN, Donahue C, Pantel HJ, Ricciardi R, Kleiman DA, Read TE, Marcello PW. Endoscopic Step Up: A Colon-Sparing Alternative to Colectomy to Improve Outcomes and Reduce Costs for Patients With Advanced Neoplastic Polyps. Dis Colon Rectum. 2020 Jun;63(6):842-849. doi: 10.1097/DCR.0000000000001645. PMID: 32118624.
102: Kaul E, Shah G, Chaulagain C, Comenzo RL. Plerixafor and G-CSF for autologous stem cell mobilization in AL amyloidosis. Bone Marrow Transplant. 2014 Sep;49(9):1233. doi: 10.1038/bmt.2014.117. Epub 2014 Jun 16. PMID: 24933207.
103: Dias A, Monteiro F, Silva J, Duarte R. Hoarseness for Two Years: Did it Start in the Lung? A Case Report. Arch Bronconeumol. 2017 Aug;53(8):457-458. English, Spanish. doi: 10.1016/j.arbres.2016.12.015. Epub 2017 Feb 24. PMID: 28238513.
104: Xingguang Lee L, Zhou P, Varga C, Fogaren T, Ho K, Ma X, Warner M, Toskic D, Kugelmass A, Comenzo RL. Daratumumab activity in relapsed or primary refractory systemic AL amyloidosis and Fcγ receptor 3A V158F polymorphisms. Amyloid. 2019 Jun;26(2):101-102. doi: 10.1080/13506129.2019.1600498. Epub 2019 May 23. PMID: 31119957.
105: Landau H, Smith M, Landry C, Chou JF, Devlin SM, Hassoun H, Bello C, Giralt S, Comenzo RL. Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis. Leukemia. 2017 Jan;31(1):136-142. doi: 10.1038/leu.2016.229. Epub 2016 Aug 18. PMID: 27560108; PMCID: PMC5220129.
106: Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, Comenzo R, Du J, Durie BGM, San Miguel J, Einsele H, Chen WM, Garderet L, Pietrantuono G, Hillengass J, Kyle RA, Moreau P, Lahuerta JJ, Landgren O, Ludwig H, Larocca A, Mahindra A, Cavo M, Mazumder A, McCarthy PL, Nouel A, Rajkumar SV, Reiman A, Riva E, Sezer O, Terpos E, Turesson I, Usmani S, Weiss BM, Palumbo A; International Myeloma Working Group. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol. 2018 Apr 1;29(4):1074. doi: 10.1093/annonc/mdx160. Erratum for: Ann Oncol. 2017 Feb 1;28(2):228-245. PMID: 28541409.
107: Gavaruzzi T, Pace U, Giandomenico F, Pucciarelli S, Bianco F, Selvaggi F, Restivo A, Asteria CR, Morpurgo E, Cuicchi D, Jovine E, Coletta D, La Torre G, Amato A, Chiappa A, Marchegiani F, Rega D, De Franciscis S, Pellino G, Zorcolo L, Lotto L, Boccia L, Spolverato G, De Salvo GL, Delrio P, Del Bianco P. Colonic J-Pouch or Straight Colorectal Reconstruction After Low Anterior Resection For Rectal Cancer: Impact on Quality of Life and Bowel Function: A Multicenter Prospective Randomized Study. Dis Colon Rectum. 2020 Nov;63(11):1511-1523. doi: 10.1097/DCR.0000000000001745. PMID: 33044292.
108: Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med. 2001 Jun 21;344(25):1951-2. doi: 10.1056/NEJM200106213442516. PMID: 11419443.
109: Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-Mancini A, Ma E, Shi H, Comenzo RL. Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):380-8. doi: 10.1016/j.clml.2014.03.005. Epub 2014 Jun 11. PMID: 25023616.
110: Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA. Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb;85(2):197-9; author reply 201-4. doi: 10.4065/mcp.2009.0559. PMID: 20118399; PMCID: PMC2813833.
111: Comenzo RL, Berkman EM. Hematopoietic stem and progenitor cells from blood: emerging uses for new components for transfusion. Transfusion. 1995 Apr;35(4):335-45. doi: 10.1046/j.1537-2995.1995.35495216084.x. PMID: 7701553.
112: George KM, Dowd RS, Nail J, Yu A, Mastroianni M, Wang AY, Arkun K, Patel A, Kryzanski J, Comenzo R, Riesenburger RI. Wild-Type Transthyretin Amyloidosis Occurring in the Ligamentum Flavum of the Cervicothoracic Spine. World Neurosurg. 2020 Oct;142:e325-e330. doi: 10.1016/j.wneu.2020.06.228. Epub 2020 Jul 8. PMID: 32652280.
113: Gertz MA, Landau H, Comenzo RL, Seldin D, Weiss B, Zonder J, Merlini G, Schönland S, Walling J, Kinney GG, Koller M, Schenk DB, Guthrie SD, Liedtke M. First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction. J Clin Oncol. 2016 Apr 1;34(10):1097-103. doi: 10.1200/JCO.2015.63.6530. Epub 2016 Feb 8. PMID: 26858336; PMCID: PMC5470113.
114: Hassoun H, Flombaum C, D'Agati VD, Rafferty BT, Cohen A, Klimek VM, Boruchov A, Kewalramani T, Reich L, Nimer SD, Comenzo RL. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease. Bone Marrow Transplant. 2008 Sep;42(6):405-12. doi: 10.1038/bmt.2008.179. Epub 2008 Jun 23. PMID: 18574442.
115: Lentzsch S, Lagos GG, Comenzo RL, Zonder JA, Pregja S, Osman K, Tsai WY, Landau H, Sanchorawala V. Updated analysis of phase 2 study of bendamustine and dexamethasone in patients with relapsed/refractory systemic light chain (AL) amyloidosis. Amyloid. 2019;26(sup1):113-114. doi: 10.1080/13506129.2019.1583200. PMID: 31343313.
116: Sanchorawala V, Wechalekar AD, Kim K, Schönland SO, Landau HJ, Kwok F, Suzuki K, Dispenzieri A, Merlini G, Comenzo RL, Cherepanov D, Hayden VC, Kumar A, Labotka R, Faller DV, Kastritis E. Quality of life and symptoms among patients with relapsed/refractory AL amyloidosis treated with ixazomib-dexamethasone versus physician's choice. Am J Hematol. 2023 May;98(5):720-729. doi: 10.1002/ajh.26866. Epub 2023 Feb 14. PMID: 36708469.
117: Chaulagain CP, Herlitz LC, Fu J, Bilani N, Lucitt C, Comenzo RL. How We Manage Systemic Immunoglobulin Heavy Chain Amyloidosis (AH Amyloidosis) and Immunoglobulin Heavy-and-Light-Chain Amyloidosis (AH/AL Amyloidosis). Clin Lymphoma Myeloma Leuk. 2020 Nov;20(11):e826-e831. doi: 10.1016/j.clml.2020.06.017. Epub 2020 Jun 28. PMID: 32703752.
118: Landau H, Hassoun H, Bello C, Hoover E, Riedel ER, Nimer SD, Comenzo RL. Consolidation with bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic AL amyloidosis. Amyloid. 2011 Jun;18 Suppl 1:135-6. doi: 10.3109/13506129.2011.574354050. Erratum in: Amyloid. 2011 Jun;18 Suppl 1:136. PMID: 21838462.
119: Fu J, Lee L, Zhou P, Fogaren T, Comenzo R. A case report - renal heavy chain amyloidosis and T-cell large granular lymphocytic leukaemia. Amyloid. 2019;26(sup1):130-131. doi: 10.1080/13506129.2019.1583180. PMID: 31343367.
120: Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G. Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium. Adv Ther. 2015 Oct;32(10):920-8. doi: 10.1007/s12325-015-0250-0. Epub 2015 Oct 23. PMID: 26498944; PMCID: PMC4635176.
121: Ma X, Zhou P, Wong SW, Warner M, Chaulagain C, Comenzo RL. siRNA targeting the κ light chain constant region: preclinical testing of an approach to nonfibrillar and fibrillar light chain deposition diseases. Gene Ther. 2016 Oct;23(10):727-733. doi: 10.1038/gt.2016.50. Epub 2016 Jun 20. PMID: 27383253.
122: Lentzsch S, Lagos GG, Comenzo RL, Zonder JA, Osman K, Pan S, Bhutani D, Pregja S, Sanchorawala V, Landau H. Bendamustine With Dexamethasone in Relapsed/Refractory Systemic Light-Chain Amyloidosis: Results of a Phase II Study. J Clin Oncol. 2020 May 1;38(13):1455-1462. doi: 10.1200/JCO.19.01721. Epub 2020 Feb 21. PMID: 32083996; PMCID: PMC7193746.
123: Zhou P, Ma X, Iyer L, Chaulagain C, Comenzo RL. One siRNA pool targeting the λ constant region stops λ light-chain production and causes terminal endoplasmic reticulum stress. Blood. 2014 May 29;123(22):3440-51. doi: 10.1182/blood-2013-10-535187. Epub 2014 Apr 10. PMID: 24723680.
124: Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Kukreti V, Vescio RA, Pei L, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL. Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis. Blood. 2014 Oct 16;124(16):2498-506. doi: 10.1182/blood-2014-04-568329. Epub 2014 Sep 8. PMID: 25202139; PMCID: PMC4199951.
125: Liberato B, Riethmuller A, Comenzo RL, Lis E, Raizer JJ. Myelopathy from Waldenström's macroglobulinemia: improvement after Rituximab therapy. J Neurooncol. 2003 Jun;63(2):207-11. doi: 10.1023/a:1023912425610. PMID: 12825826.
126: Lebovic D, Hoffman J, Levine BM, Hassoun H, Landau H, Goldsmith Y, Maurer MS, Steingart RM, Cohen AD, Comenzo RL. Predictors of survival in patients with systemic light-chain amyloidosis and cardiac involvement initially ineligible for stem cell transplantation and treated with oral melphalan and dexamethasone. Br J Haematol. 2008 Nov;143(3):369-73. doi: 10.1111/j.1365-2141.2008.07327.x. Epub 2008 Aug 4. PMID: 18691169.
127: Fu J, Lee LX, Zhou P, Fogaren T, Varga C, Comenzo RL. A Case of T-Cell Large Granular Lymphocytic Leukemia and Renal Immunoglobulin Heavy Chain Amyloidosis. Am J Case Rep. 2019 Jan 11;20:43-47. doi: 10.12659/AJCR.912282. PMID: 30631033; PMCID: PMC6345110.
128: Akpek G, Lenz G, Lee SM, Sanchorawala V, Wright DG, Colarusso T, Waraska K, Lerner A, Vosburgh E, Skinner M, Comenzo RL. Immunologic recovery after autologous blood stem cell transplantation in patients with AL-amyloidosis. Bone Marrow Transplant. 2001 Dec;28(12):1105-9. doi: 10.1038/sj.bmt.1703298. PMID: 11803350.
129: Cohen AD, Zhou P, Xiao Q, Fleisher M, Kalakonda N, Akhurst T, Chitale DA, Moscowitz C, Dhodapkar MV, Teruya-Feldstein J, Filippa D, Comenzo RL. Systemic AL amyloidosis due to non-Hodgkin's lymphoma: an unusual clinicopathologic association. Br J Haematol. 2004 Feb;124(3):309-14. doi: 10.1046/j.1365-2141.2003.04779.x. PMID: 14717777.
130: Landau H, Pandit-Taskar N, Hassoun H, Cohen A, Lesokhin A, Lendvai N, Drullinsky P, Schulman P, Jhanwar S, Hoover E, Bello C, Riedel E, Nimer SD, Comenzo RL. Bortezomib, liposomal doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective treatment for patients with newly diagnosed multiple myeloma with Internatinal Staging System stage II or III, or extramedullary disease. Leuk Lymphoma. 2012 Feb;53(2):275-81. doi: 10.3109/10428194.2011.606943. Epub 2011 Sep 23. PMID: 21824051.
131: Hassoun H, Reich L, Klimek VM, Dhodapkar M, Cohen A, Kewalramani T, Zimman R, Drake L, Riedel ER, Hedvat CV, Teruya-Feldstein J, Filippa DA, Fleisher M, Nimer SD, Comenzo RL. Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. Br J Haematol. 2006 Jan;132(2):155-61. doi: 10.1111/j.1365-2141.2005.05848.x. PMID: 16398649.
132: Dubrey SW, Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, Vescio RA, Bladé J, Heffner LT, Hassoun H, Liu X, Enny C, Ramaswami P, Elsayed Y, Van De Velde H, Mortimer S, Cakana A, Comenzo RL; Velcade Can2007 Study Group. Bortezomib in a phase 1 trial for patients with relapsed AL amyloidosis: cardiac responses and overall effects. QJM. 2011 Nov;104(11):957-70. doi: 10.1093/qjmed/hcr105. Epub 2011 Jul 13. PMID: 21752867.
133: Ma X, Wong SW, Zhou P, Chaulagain CP, Doshi P, Klein AK, Sprague K, Kugelmass A, Toskic D, Warner M, Miller KB, Lee L, Varga C, Comenzo RL. Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or impaired progenitor cell growth. Exp Hematol Oncol. 2018 Oct 16;7:27. doi: 10.1186/s40164-018-0119-4. PMID: 30356940; PMCID: PMC6192105.
134: Dhakal B, D'Souza A, Callander N, Chhabra S, Fraser R, Davila O, Anderson K, Assal A, Badawy SM, Berdeja J, Cerny J, Comenzo R, Chakraborty R, Peter Gale R, Kamble R, Kharfan-Dabaja MA, Krem M, Ganguly S, Janakiram M, Kansagra A, Munker R, Murthy H, Patel S, Kumar S, Shah N, Qazilbash M, Hari P. Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. Br J Haematol. 2020 Nov;191(3):442-452. doi: 10.1111/bjh.16987. Epub 2020 Oct 23. PMID: 33094839; PMCID: PMC7990054.
135: Nguyen VP, Rosenberg A, Mendelson LM, Comenzo RL, Varga C, Sanchorawala V. Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis. Amyloid. 2018 Sep;25(3):156-159. doi: 10.1080/13506129.2018.1490261. Epub 2018 Jul 21. PMID: 30032640.
136: Landau H, Hassoun H, Rosenzweig MA, Maurer M, Liu J, Flombaum C, Bello C, Hoover E, Riedel E, Giralt S, Comenzo RL. Bortezomib and dexamethasone consolidation following risk-adapted melphalan and stem cell transplantation for patients with newly diagnosed light-chain amyloidosis. Leukemia. 2013 Apr;27(4):823-8. doi: 10.1038/leu.2012.274. Epub 2012 Sep 27. PMID: 23014566.
137: Zhou P, Teruya-Feldstein J, Lu P, Fleisher M, Olshen A, Comenzo RL. Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan. Blood. 2008 Jan 15;111(2):549-57. doi: 10.1182/blood-2007-05-090852. Epub 2007 Nov 2. PMID: 17982021; PMCID: PMC2200859.
138: Reece DE, Sanchorawala V, Hegenbart U, Merlini G, Palladini G, Fermand JP, Vescio RA, Liu X, Elsayed YA, Cakana A, Comenzo RL; VELCADE CAN2007 Study Group. Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood. 2009 Aug 20;114(8):1489-97. doi: 10.1182/blood-2009-02-203398. Epub 2009 Jun 4. PMID: 19498019.
139: Comenzo RL, Hassoun H, Kewalramani T, Klimek V, Dhodapkar M, Reich L, Teruya-Feldstein J, Fleisher M, Filippa D, Nimer SD. Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation. Leukemia. 2006 Feb;20(2):345-9. doi: 10.1038/sj.leu.2404003. PMID: 16319952.
140: Comenzo RL, Zhou P, Fleisher M, Clark B, Teruya-Feldstein J. Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins. Blood. 2006 May 1;107(9):3489-91. doi: 10.1182/blood-2005-10-4148. Epub 2006 Jan 26. PMID: 16439680.
141: George KM, Hernandez NS, Breton J, Cooper B, Dowd RS, Nail J, Yu A, Mastroianni M, Wang A, Godara A, Zhang D, Arkun K, Patel AR, Varga C, Soto O, Kryzanski J, Comenzo R, Riesenburger R. Lumbar ligamentum flavum burden: Evaluating the role of ATTRwt amyloid deposition in ligamentum flavum thickness at all lumbar levels. Clin Neurol Neurosurg. 2021 Jul;206:106708. doi: 10.1016/j.clineuro.2021.106708. Epub 2021 May 25. PMID: 34053807.
142: Amon CC, Paley AR, Forbes JA, Guzman LV, Rajwani AA, Trzcinka A, Comenzo RL, Drzymalski DM. Implementing structured handoffs to verify operating room blood delivery using a quality academy training program: an interrupted time-series analysis. Int J Qual Health Care. 2021 Apr 16;33(2):mzab061. doi: 10.1093/intqhc/mzab061. PMID: 33825860.
143: Gertz M, Adams D, Ando Y, Beirão JM, Bokhari S, Coelho T, Comenzo RL, Damy T, Dorbala S, Drachman BM, Fontana M, Gillmore JD, Grogan M, Hawkins PN, Lousada I, Kristen AV, Ruberg FL, Suhr OB, Maurer MS, Nativi-Nicolau J, Quarta CC, Rapezzi C, Witteles R, Merlini G. Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner. BMC Fam Pract. 2020 Sep 23;21(1):198. doi: 10.1186/s12875-020-01252-4. PMID: 32967612; PMCID: PMC7513485.
144: Shah G, Kaul E, Fallo S, Cossor F, Smith H, Sprague K, Klein A, Miller K, Comenzo R. Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients. Clin Ther. 2013 Oct;35(10):1614-20. doi: 10.1016/j.clinthera.2013.08.015. Epub 2013 Sep 26. Erratum in: Clin Ther. 2014 Apr 1;36(4):611. PMID: 24075726.
145: Zhou P, Hoffman J, Landau H, Hassoun H, Iyer L, Comenzo RL. Clonal plasma cell pathophysiology and clinical features of disease are linked to clonal plasma cell expression of cyclin D1 in systemic light-chain amyloidosis. Clin Lymphoma Myeloma Leuk. 2012 Feb;12(1):49-58. doi: 10.1016/j.clml.2011.09.217. Epub 2011 Nov 18. PMID: 22100494.
146: Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Vescio RA, Liu K, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL. Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood. 2011 Jul 28;118(4):865-73. doi: 10.1182/blood-2011-02-334227. Epub 2011 May 11. PMID: 21562045.
147: Sun GH, Patel V, Moreno-Duarte I, Zahedi F, Ursprung E, Couper G, Chen FY, Welsby IJ, Comenzo R, Kao G, Cobey FC. Intraoperative Administration of 4-Factor Prothrombin Complex Concentrate Reduces Blood Requirements in Cardiac Transplantation. J Cardiothorac Vasc Anesth. 2018 Feb;32(1):161-167. doi: 10.1053/j.jvca.2017.08.011. Epub 2017 Aug 3. PMID: 29198634.
148: Hedvat CV, Comenzo RL, Teruya-Feldstein J, Olshen AB, Ely SA, Osman K, Zhang Y, Kalakonda N, Nimer SD. Insights into extramedullary tumour cell growth revealed by expression profiling of human plasmacytomas and multiple myeloma. Br J Haematol. 2003 Sep;122(5):728-44. doi: 10.1046/j.1365-2141.2003.04481.x. Erratum in: Br J Haematol. 2003 Nov;123(3):563. PMID: 12930383.
149: Kaul E, Pilichowska M, Vullaganti M, Madan N, Comenzo RL. Twists and turns of determining amyloid type and amyloid-related organ damage: discordance and clinical skepticism in the era of proteomic typing. Amyloid. 2014 Mar;21(1):62-5. doi: 10.3109/13506129.2013.856779. Epub 2013 Nov 20. PMID: 24256111.
150: Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H, Levine B, Filippa DA, Riedel E, Kewalramani T, Stubblefield MD, Fleisher M, Nimer S, Comenzo RL. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial. Br J Haematol. 2007 Oct;139(2):224-33. doi: 10.1111/j.1365-2141.2007.06783.x. PMID: 17897298.
151: Dispenzieri A, Merlini G, Comenzo RL. Amyloidosis 2008 BMT Tandem Meetings (February 13-17, San Diego). Biol Blood Marrow Transplant. 2008 Jan;14(Supplement 1):6-11. doi: 10.1016/j.bbmt.2007.10.026. PMID: 19122741; PMCID: PMC2330327.
152: Comenzo RL, Zhang Y, Martinez C, Osman K, Herrera GA. The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood. 2001 Aug 1;98(3):714-20. doi: 10.1182/blood.v98.3.714. PMID: 11468171.
153: Zhou P, Kalakonda N, Comenzo RL. Changes in gene expression profiles of multiple myeloma cells induced by arsenic trioxide (ATO): possible mechanisms to explain ATO resistance in vivo. Br J Haematol. 2005 Mar;128(5):636-44. doi: 10.1111/j.1365-2141.2005.05369.x. PMID: 15725085.
154: Comenzo RL, Wally J, Kica G, Murray J, Ericsson T, Skinner M, Zhang Y. Clonal immunoglobulin light chain variable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation. Br J Haematol. 1999 Sep;106(3):744-51. doi: 10.1046/j.1365-2141.1999.01591.x. PMID: 10468868.
155: Wong SW, Larivee D, Warner M, Sprague KA, Fogaren T, Comenzo RL. Stem cell transplantation in patients with systemic AL amyloidosis referred for transplant after suboptimal responses to bortezomib-based initial therapy. Bone Marrow Transplant. 2017 Jun;52(6):936-937. doi: 10.1038/bmt.2017.47. Epub 2017 Apr 10. PMID: 28394371.
156: Flomenberg N, Comenzo RL, Badel K, Calandra G. Plerixafor (Mozobil) alone to mobilize hematopoietic stem cells from multiple myeloma patients for autologous transplantation. Biol Blood Marrow Transplant. 2010 May;16(5):695-700. doi: 10.1016/j.bbmt.2009.12.538. Epub 2010 Jan 11. PMID: 20067838.
157: Comenzo RL. Advances in the treatment of plasma cell diseases. Hosp Pract (1995). 1996 Aug 15;31(8):67-70, 73-4, 79-84 passim. doi: 10.1080/21548331.1996.11443332. PMID: 9119932.
158: Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Freytes C, Gale RP, Ganguly S, Hamadani M, Hashmi S, Holmberg L, Hossain N, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Kyle R, Kumar S, Lazarus H, Lee C, Maiolino A, Marks DI, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson RF, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, Wirk BM, Yared J, Krishnan A, Mark T, Nieto Y, Hari P. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Feb;23(2):269-277. doi: 10.1016/j.bbmt.2016.11.011. Epub 2016 Nov 15. PMID: 27864161; PMCID: PMC5346183.
159: Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Lentzsch S, Munshi N, Niesvizky R, San Miguel J, Ludwig H, Bergsagel L, Blade J, Lonial S, Anderson KC, Tosi P, Sonneveld P, Sezer O, Vesole D, Cavo M, Einsele H, Richardson PG, Durie BG, Rajkumar SV; International Myeloma Working Group. Mobilization in myeloma revisited: IMWG consensus perspectives on
stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. 2009 Aug 27;114(9):1729-35. doi: 10.1182/blood-2009-04-205013. Epub 2009 Jun 26. PMID: 19561323.
160: Comenzo RL, Malachowski ME, Miller KB, Erban JJ, Schenkein DP, Desforges JF, Berkman EM. Engraftment with peripheral blood stem cells collected by large-volume leukapheresis for patients with lymphoma. Transfusion. 1992 Oct;32(8):729-31. doi: 10.1046/j.1537-2995.1992.32893032099.x. PMID: 1357788.
161: Comenzo RL, Michelle D, LeBlanc M, Wally J, Zhang Y, Kica G, Karandish S, Arkin CF, Wright DG, Skinner M, McMannis J. Mobilized CD34+ cells selected as autografts in patients with primary light-chain amyloidosis: rationale and application. Transfusion. 1998 Jan;38(1):60-9. doi: 10.1046/j.1537-2995.1998.38198141500.x. PMID: 9482396.
162: Landau HJ, McNeely SC, Nair JS, Comenzo RL, Asai T, Friedman H, Jhanwar SC, Nimer SD, Schwartz GK. The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells. Mol Cancer Ther. 2012 Aug;11(8):1781-8. doi: 10.1158/1535-7163.MCT-11-0949. Epub 2012 May 31. PMID: 22653969.
163: Hoffman J, Jhanwar S, Comenzo RL. AL amyloidosis and progression to multiple myeloma with gain(1q). Br J Haematol. 2009 Mar;144(6):963-4. doi: 10.1111/j.1365-2141.2008.07536.x. Epub 2008 Dec 19. PMID: 19120348.
164: Jaccard A, Comenzo RL, Hari P, Hawkins PN, Roussel M, Morel P, Macro M, Pellegrin JL, Lazaro E, Mohty D, Mercie P, Decaux O, Gillmore J, Lavergne D, Bridoux F, Wechalekar AD, Venner CP. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III). Haematologica. 2014 Sep;99(9):1479-85. doi: 10.3324/haematol.2014.104109. Epub 2014 May 23. PMID: 24859879; PMCID: PMC4562537.
165: Carrillo Norte JA. Interacciones farmacológicas y relevancia clínica. Todo comenzó con el queso [Drug interactions and clinical relevance: it all began with cheese]. Rev Enferm. 2012 Apr;35(4):8-18. Spanish. PMID: 22745995.
166: Comenzo RL, Vosburgh E, Simms RW, Bergethon P, Sarnacki D, Finn K, Dubrey S, Faller DV, Wright DG, Falk RH, Skinner M. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood. 1996 Oct 1;88(7):2801-6. PMID: 8839879.
167: Shah GL, Winn A, Lin PJ, Klein A, Sprague KA, Smith HP, Buchsbaum R, Cohen JT, Miller KB, Comenzo R, Parsons SK. Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare. Bone Marrow Res. 2016;2016:3645623. doi: 10.1155/2016/3645623. Epub 2016 Oct 18. PMID: 27830092; PMCID: PMC5088316.
168: D'Souza A, Dispenzieri A, Wirk B, Zhang MJ, Huang J, Gertz MA, Kyle RA, Kumar S, Comenzo RL, Peter Gale R, Lazarus HM, Savani BN, Cornell RF, Weiss BM, Vogl DT, Freytes CO, Scott EC, Landau HJ, Moreb JS, Costa LJ, Ramanathan M, Callander NS, Kamble RT, Olsson RF, Ganguly S, Nishihori T, Kindwall-Keller TL, Wood WA, Mark TM, Hari P. Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. J Clin Oncol. 2015 Nov 10;33(32):3741-9. doi: 10.1200/JCO.2015.62.4015. Epub 2015 Sep 14. PMID: 26371138; PMCID: PMC4737858.
169: Klingemann H, Grodman C, Cutler E, Duque M, Kadidlo D, Klein AK, Sprague KA, Miller KB, Comenzo RL, Kewalramani T, Yu N, Van Etten RA, McKenna DH. Autologous stem cell transplant recipients tolerate haploidentical related-donor natural killer cell-enriched infusions. Transfusion. 2013 Feb;53(2):412-8; quiz 411. doi: 10.1111/j.1537-2995.2012.03764.x. Epub 2012 Jun 28. PMID: 22738379; PMCID: PMC3549470.
170: Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A, Schönland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 2017 Aug 3;130(5):597-605. doi: 10.1182/blood-2017-03-771220. Epub 2017 May 26. Erratum in: Blood. 2020 Mar 26;135(13):1071. PMID: 28550039; PMCID: PMC6911836.
171: Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar A, Hawkins PN, Schönland S, Hegenbart U, Comenzo R, Kastritis E, Dimopoulos MA, Jaccard A, Klersy C, Merlini G. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J Clin Oncol. 2012 Dec 20;30(36):4541-9. doi: 10.1200/JCO.2011.37.7614. Epub 2012 Oct 22. PMID: 23091105.
172: Wally J, Kica G, Zhang Y, Ericsson T, Connors LH, Benson MD, Liepnieks JJ, Murray J, Skinner M, Comenzo RL. Identification of a novel substitution in the constant region of a gene coding for an amyloidogenic kappa1 light chain. Biochim Biophys Acta. 1999 May 31;1454(1):49-56. doi: 10.1016/s0925-4439(99)00019-8. PMID: 10354514.
173: Apridonidze T, Steingart RM, Comenzo RL, Hoffman J, Goldsmith Y, Bella JN, Landau H, Liu JE. Clinical and echocardiographic correlates of elevated troponin in amyloid light-chain cardiac amyloidosis. Am J Cardiol. 2012 Oct 15;110(8):1180-4. doi: 10.1016/j.amjcard.2012.05.061. Epub 2012 Jul 6. PMID: 22770934.
174: Hussein MA, Vrionis FD, Allison R, Berenson J, Berven S, Erdem E, Giralt S, Jagannath S, Kyle RA, LeGrand S, Pflugmacher R, Raje N, Rajkumar SV, Randall RL, Roodman D, Siegel D, Vescio R, Zonder J, Durie BG; International Myeloma Working Group. The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement. Leukemia. 2008 Aug;22(8):1479-84.
doi: 10.1038/leu.2008.127. Epub 2008 May 29. Erratum in: Leukemia. 2008 Aug;22(8):1649. Randall, L [corrected to Randall, RL]. PMID: 18509352.
175: Mulloy JC, Cammenga J, Berguido FJ, Wu K, Zhou P, Comenzo RL, Jhanwar S, Moore MA, Nimer SD. Maintaining the self-renewal and differentiation potential of human CD34+ hematopoietic cells using a single genetic element. Blood. 2003 Dec 15;102(13):4369-76. doi: 10.1182/blood-2003-05-1762. Epub 2003 Aug 28. PMID: 12946995.
176: Miller KB, Schenkein DP, Comenzo R, Erban JK, Fogaren T, Hirsch CA, Berkman E, Rabson A. Adjusted-dose continuous-infusion cyclosporin A to prevent graft-versus-host disease following allogeneic bone marrow transplantation. Ann Hematol. 1994 Jan;68(1):15-20. doi: 10.1007/BF01695914. PMID: 8110873.
177: Comenzo RL, Malachowski ME, Meissner HC, Fulton DR, Berkman EM. Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease. J Pediatr. 1992 Jun;120(6):926-8. doi: 10.1016/s0022-3476(05)81964-x. PMID: 1593353.
178: Gupta S, Zhou P, Hassoun H, Kewalramani T, Reich L, Costello S, Drake L, Klimek V, Dhodapkar M, Teruya-Feldstein J, Hedvat C, Kalakonda N, Fleisher M, Filippa D, Qin J, Nimer SD, Comenzo RL. Hematopoietic stem cell mobilization with intravenous melphalan and G-CSF in patients with chemoresponsive multiple myeloma: report of a phase II trial. Bone Marrow Transplant. 2005 Mar;35(5):441-7. doi: 10.1038/sj.bmt.1704779. PMID: 15640822.
179: Comenzo RL, Sanchorawala V, Fisher C, Akpek G, Farhat M, Cerda S, Berk JL, Dember LM, Falk R, Finn K, Skinner M, Vosburgh E. Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br J Haematol. 1999 Mar;104(3):553-9. doi: 10.1046/j.1365-2141.1999.01216.x. PMID: 10086794.
180: Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, Dember LM, Berk JL, Akpek G, LaValley M, O'hara C, Arkin CF, Wright DG, Skinner M. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood. 1998 May 15;91(10):3662-70. PMID: 9573002.
181: Zhou P, Zhang Y, Martinez C, Kalakonda N, Nimer SD, Comenzo RL. Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination. Blood. 2003 Jul 15;102(2):477-9. doi: 10.1182/blood-2002-12-3674. Epub 2003 Mar 20. PMID: 12649134.
182: Zhou P, Comenzo RL, Olshen AB, Bonvini E, Koenig S, Maslak PG, Fleisher M, Hoffman J, Jhanwar S, Young JW, Nimer SD, Boruchov AM. CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy. Blood. 2008 Apr 1;111(7):3403-6. doi: 10.1182/blood-2007-11-125526. Epub 2008 Jan 23. PMID: 18216299; PMCID: PMC2275009.
183: Teruya-Feldstein J, Chiao E, Filippa DA, Lin O, Comenzo R, Coleman M, Portlock C, Noy A. CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients. Ann Oncol. 2004 Nov;15(11):1673-9. doi: 10.1093/annonc/mdh399. PMID: 15520070.
184: Comenzo RL, Malachowski ME, Miller KB, Erban JK, Schenkein DP, Desforges JF, Berkman EM. Large-volume leukapheresis for collection of mononuclear cells for hematopoietic rescue in Hodgkin's disease. Transfusion. 1995 Jan;35(1):42-5. doi: 10.1046/j.1537-2995.1995.35195090659.x. PMID: 7998067.
185: Urbano-Moral JA, Gangadharamurthy D, Comenzo RL, Pandian NG, Patel AR. Three-dimensional Speckle Tracking Echocardiography in Light Chain Cardiac Amyloidosis: Examination of Left and Right Ventricular Myocardial Mechanics Parameters. Rev Esp Cardiol (Engl Ed). 2015 Aug;68(8):657-64. doi: 10.1016/j.rec.2015.01.009. Epub 2015 Jun 17. PMID: 26092748.
186: Pedranzini L, Dechow T, Berishaj M, Comenzo R, Zhou P, Azare J, Bornmann W, Bromberg J. Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells. Cancer Res. 2006 Oct 1;66(19):9714-21. doi: 10.1158/0008-5472.CAN-05-4280. PMID: 17018630.
187: Malachowski ME, Comenzo RL, Hillyer CD, Tiegerman KO, Berkman EM. Large-volume leukapheresis for peripheral blood stem cell collection in patients with hematologic malignancies. Transfusion. 1992 Oct;32(8):732-5. doi: 10.1046/j.1537-2995.1992.32893032100.x. PMID: 1357789.
188: Dowd RS, Nail TJ, Arkun K, Kryzanski J, Soto O, Fogaren T, Harrington K, Patel A, Comenzo R, Riesenburger RI. Where Neurosurgery Meets Heart Failure: A Case Report of a Patient with Amyloid Transthyretin Wild Type in the Ligamentum Flavum and Cardiac Tissue with Bilateral Carpal Tunnel Syndrome. World Neurosurg. 2019 Nov;131:104-107. doi: 10.1016/j.wneu.2019.07.172. Epub 2019 Jul
29. PMID: 31369882.
189: Raje N, Kica G, Chauhan D, Zhang Y, Teoh G, Treon SP, Hideshima T, Deng JH, Gao SJ, Alsina M, Wally J, Davies FE, Tai YT, Pinkus GS, Pinkus JL, Skinner M, Comenzo RL, Anderson KC. Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis. Amyloid. 2000 Jun;7(2):126-32. doi: 10.3109/13506120009146250. PMID: 10842716.
190: Pozotrigo M, Adel N, Landau H, Lesokhin A, Lendvai N, Chung DJ, Chimento D, Riedel E, Chen X, Reich L, Comenzo R, Giralt S, Hassoun H. Factors impacting stem cell mobilization failure rate and efficiency in multiple myeloma in the era of novel therapies: experience at Memorial Sloan Kettering Cancer Center. Bone Marrow Transplant. 2013 Aug;48(8):1033-9. doi: 10.1038/bmt.2012.281. Epub 2013 Jan 21. PMID: 23334269.
191: Sanchorawala V, Wright DG, Seldin DC, Falk RH, Finn KT, Dember LM, Berk JL, Quillen K, Anderson JJ, Comenzo RL, Skinner M. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant. 2004 Feb;33(4):381-8. doi: 10.1038/sj.bmt.1704346. PMID: 14676787.
192: Shah GL, Winn AN, Lin PJ, Klein A, Sprague KA, Smith HP, Buchsbaum R, Cohen JT, Miller KB, Comenzo R, Parsons SK. Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results-Medicare Database. Biol Blood Marrow Transplant. 2015 Oct;21(10):1823-9. doi: 10.1016/j.bbmt.2015.05.013. Epub 2015 May 30. PMID: 26033281; PMCID: PMC4933291.
193: Comenzo RL, Malachowski ME, Rohrer RJ, Freeman RB, Rabson A, Berkman EM. Anomalous ABO phenotype in a child after an ABO-incompatible liver transplantation. N Engl J Med. 1992 Mar 26;326(13):867-70. doi: 10.1056/NEJM199203263261305. PMID: 1542324.
194: Comenzo R, Roth D, Desforges JF, Berkman EM. Trisomy 13q in a case of acute leukemia with lineage inconsistency. Cancer Genet Cytogenet. 1991 Aug;55(1):107-11. doi: 10.1016/0165-4608(91)90243-n. PMID: 1913596.
195: Alsina M, Trudel S, Furman RR, Rosen PJ, O'Connor OA, Comenzo RL, Wong A, Kunkel LA, Molineaux CJ, Goy A. A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res. 2012 Sep 1;18(17):4830-40. doi: 10.1158/1078-0432.CCR-11-3007. Epub 2012 Jul 3. PMID: 22761464.
196: Mathew S, Adel N, Rice RD, Panageas K, Duck ET, Comenzo RL, Kewalramani T, Nimer SD. Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients. Bone Marrow Transplant. 2010 Oct;45(10):1522-7. doi: 10.1038/bmt.2009.373. Epub 2010 Jan 11. PMID: 20062102.
197: Comenzo RL, Vosburgh E, Weintraub LR, Tansan S, Arkin CF, Wright DG. Collection of mobilized blood progenitor cells for hematopoietic rescue by large-volume leukapheresis. Transfusion. 1995 Jun;35(6):493-7. doi: 10.1046/j.1537-2995.1995.35695288768.x. PMID: 7770900.
198: Comenzo R, Malachowski M, Berkman E. Clinical correlation of positive direct antiglobulin tests in patients with sickle cell disease. Immunohematology. 1992;8(1):13-6. PMID: 15946047.
199: Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, LeLeu X, Hulin C, Klein SK, Sonneveld P, Siegel D, Bladé J, Goldschmidt H, Jagannath S, Miguel JS, Orlowski R, Palumbo A, Sezer O, Rajkumar SV, Durie BG; International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs
and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012 Jan;26(1):149-57. doi: 10.1038/leu.2011.196. Epub 2011 Jul 29. Erratum in: Leukemia. 2012 May;26(5):1153. Nari, Hareth [corrected to Nahi, Hareth]. PMID: 21799510; PMCID: PMC4109061.
200: Dhodapkar MV, Osman K, Teruya-Feldstein J, Filippa D, Hedvat CV, Iversen K, Kolb D, Geller MD, Hassoun H, Kewalramani T, Comenzo RL, Coplan K, Chen YT, Jungbluth AA. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun. 2003 Jul 23;3:9. PMID: 12875607.
201: Goldsmith YB, Liu J, Chou J, Hoffman J, Comenzo RL, Steingart RM. Frequencies and types of arrhythmias in patients with systemic light-chain amyloidosis with cardiac involvement undergoing stem cell transplantation on telemetry monitoring. Am J Cardiol. 2009 Oct 1;104(7):990-4. doi: 10.1016/j.amjcard.2009.05.040. PMID: 19766769.
202: Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E 3rd, Antin JH, Comenzo R, Goodman S, Hari P, Laport G, Qazilbash MH, Rowley S, Sahebi F, Somlo G, Vogl DT, Weisdorf D, Ewell M, Wu J, Geller NL, Horowitz MM, Giralt S, Maloney DG; Blood Marrow Transplant Clinical Trials Network (BMT CTN). Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011 Dec;12(13):1195-203. doi: 10.1016/S1470- 045(11)70243-1. Epub 2011 Sep 29. PMID: 21962393; PMCID: PMC3611089.
203: Hillyer CD, Comenzo RL, Miller KB, Schenkein DP, Tiegerman KO, Fogaren TA, Wazer DE, Parker L, Abrams RA, Desforges JF, et al. Prompt engraftment using autologous peripheral blood stem cells for double autologous bone marrow rescue. Am J Hematol. 1991 Feb;36(2):152-3. doi: 10.1002/ajh.2830360217. PMID: 2012067.
204: Liebman HA, Comenzo R, Allen ST, Dilorio JM. A glycosaminoglycan inhibitor of thrombin: a new mechanism for abnormal hemostatic assays in cancer. Am J Hematol. 1991 Sep;38(1):24-9. doi: 10.1002/ajh.2830380105. PMID: 1897511.
205: Comenzo RL, Steingart RM, Cohen AD. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2008 Jan 3;358(1):92; author reply 92-3. PMID: 18175384.
206: Stevens JM, Patton WN, Heaton DC, Spearing RL, Shaw G, Bowie D, Smyth D, Comenzo R. Autologous PBSCT in patients with cardiac amyloidosis. Bone Marrow Transplant. 2000 Sep;26(5):588-9. doi: 10.1038/sj.bmt.1702551. PMID: 11019855.
